Arthrosi snags $153M in pursuit of a new gout drug

▤ Summary

Arthrosi Therapeutics raised $153 million in a Series E round to speed up development of a new gout treatment. The company is advancing AR882, a next-generation URAT1 inhibitor designed to lower uric acid levels more selectively than older options. Its lead program has already completed mid-stage testing, and two Phase 3 trials are fully enrolled with results expected in the second quarter of 2026. The funding supports late-stage clinical progress in a market where current gout therapies still leave meaningful unmet need.

$ Funding

▦ Linked Companies